Robin Carhart-Harris, Ph.D
Dr. Carhart-Harris is the Head of the Centre for Psychedelic Research in the Department of Brain Sciences at Imperial College London where he has published numerous clinical trials studying the effects of psychedelics on the brain. While there, he has designed a number of functional brain imaging studies with psilocybin (magic mushrooms), LSD, MDMA (ecstasy) and DMT (ayahuasca). Dr. Carhart-Harris has over 90 published papers in peer-reviewed scientific journals; 5 of which rank in the top 10 for annual citation rate in the field of psychedelic science, including the top 2 overall. Robin's research has featured in major national and international media and he has given a popular TEDx talk and has been a leading voice for psychedelic medicine at the World Economic Forum in Davos. His talks on psychedelic-assisted therapy play a significant role in the development of psychedelics as novel pharmaceuticals for the treatment of disorders currently underserved with existing therapies and he will play a crucial role in helping to shape Tryp's upcoming clinical trials.
Dr Carhart-Harris obtained his PhD in Psychopharmacology from the University of Bristol, and prior to that, an MA in Psychoanalysis at Brunel University. He has an honorary position at the University of Oxford.
Rachel Wevrick, Ph.D
Dr. Wevrick is Professor, Department of Medical Genetics, at University of Alberta. Her research is focused on the genetic, molecular, and physiological basis of abnormal neurodevelopment, growth and metabolism in developmental disorders affecting children. Her specific areas of interest include: Prader-Willi syndrome (“PWS”) and Translational research in PWS, Schaaf-Yang syndrome, and other neurodevelopmental disabilities that are caused by de novo or inherited genetic mutations that affect the function of the brain and nervous system including Bardet-Biedl syndrome, Tourette syndrome, and severe early onset obesity with intellectual disability. She earned her PhD from the Department of Molecular and Medical Genetics, University of Toronto and completed post-doctoral fellowships in the Department of Genetics at The Hospital for Sick Children Research Institute, and at Howard Hughes Medical Institute, Stanford University School of Medicine.
Derek Ott, M.D.
Dr. Ott is an associate clinical professor of psychiatry at UCLA School of Medicine, the director of the UCLA Pediatric Neuropsychiatry Clinic and a psychiatric consultant for Westside and Frank D Lanterman Regional Centers in Los Angeles. He is board certified physician in both child and adolescent as well as adult psychiatry. Dr. Ott graduated from Stanford University with honors and a degree in human biology. He then attended the University of Illinois in Urbana-Champaign, where he completed his medical and graduate training (Masters in Neuroscience). Dr. Ott began his clinical training in psychiatry at the University of California-Los Angeles Resnick Neuropsychiatric Hospital in Westwood, where he completed a residency in Adult Psychiatry , as well as a fellowship in Child and Adolescent Psychiatry. Following this clinical training, Dr. Ott participated in a NIMH sponsored post-doctoral fellowship which focused on psychopathology in pediatric epilepsy. Dr. Ott has particular expertise in the areas of neuropsychiatry, developmental disabilities, attention-deficit hyperactivity disorder and childhood psychosis. He has extensive experience working with individuals with neurological disorders, developmental disabilities (i.e. autism and intellectual disability), as well as comorbid behavioral/psychiatric disorder. His private practice focuses on psychopharmacology in children, adolescents, and adults.
William K. Schmidt, Ph.D
Dr. William K. Schmidt serves as an expert on pain medicine pharmaceutical development with pharmaceutical and biotech companies throughout North America, Europe, Asia, Latin America, and Australia. He currently sits on the Scientific or Medical Advisory Boards of 5 biotech companies. He is the Parliamentarian and a Past-President of the Eastern Pain Association. Dr. Schmidt has received many awards throughout his career including the John J. Bonica award for the development of new analgesics and for his sustained contributions to the educational efforts of the Eastern Pain Association in 2014. He is the co-editor of "Pain: Current Understanding, Emerging, Therapies, and Novel Approaches to Drug Discovery" (Marcel Dekker, 2003). He joined DuPont Pharmaceuticals (later the DuPont Merck Pharmaceutical Company) where he helped to develop nalbuphine (Nubain®), naltrexone (Trexan®, ReVia®) and the oxycodone-ibuprofen formulation used in Combunox™. He also led the clinical teams in the development of Entereg® (alvimopan) and Acelex® (polmacoxib). Dr. Schmidt continues to chair the annual Arrowhead Pain Summit (2010-2021) and the Pharmaceutical Roundtable / Innovations in Pain Research for the Eastern Pain Association (2003-2021).